Grant: Proof of Principle Program - Phase I
Université de Montréal
$145,412.00
The ARiBo technology for isolation of ribonucleoprotein complexes
FY 2011-12
Summary
An emerging interest in biomedical research lies in the understanding of the mechanisms regulating functionally important and disease-associated RNA molecules. For example, newly discovered micro RNAs are associated with human diseases, including neurodegenerative diseases, immune diseases, cardiovascular diseases and several forms of cancers. Since these microRNAs and other RNAs are regulated through the formation of ribonucleoprotein complexes, the identification and characterization of these complexes is currently an area of intense scientific interest both from a basic and applied perspective. As a result, there is a high demand for novel tools that can isolate proteins associated with a specific target RNA.
Over the past few years, we have developed the ARiBo technology, which provides a quick and efficient procedure for purifying RNA. Although this procedure was originally developed to rapidly purify in vitro transcribed RNA, it also shows great potential for isolating ribonucleoprotein complexes associated with a specific target RNA. Here, we propose to exploit the ARiBo technology to further develop reagents and procedures that can be packaged as kits for isolating ribonucleoprotein complexes. Our technology may become the ultimate solution for isolating RNA-protein complexes in riboproteomics approaches with potential market opportunities in many fields, including in identifying and validating new drug targets. Thus the research proposed here has great potential to open new possibilities for life sciences research and have a positive impact on the health of Canadians as well as upon the Canadian economy.
Department
Program
Proof of Principle Program - Phase I
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
256796
Name
Legault Pascale
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
The ARiBo technology for isolation of ribonucleoprotein complexes
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$145,412
Cihrequipment2
$13,349
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Activatable Ribozymes; Affinity Purification Of Rna; Isolation Of Rnp Complexes; Lambda Boxb Rna; Lambda N Peptide; Micro Rna; Ribonucleoprotein Complexes; Riboproteomics; Rna-Protein Interactions; Tagged Rna
Abstract
An emerging interest in biomedical research lies in the understanding of the mechanisms regulating functionally important and disease-associated RNA molecules. For example, newly discovered micro RNAs are associated with human diseases, including neurodegenerative diseases, immune diseases, cardiovascular diseases and several forms of cancers. Since these microRNAs and other RNAs are regulated through the formation of ribonucleoprotein complexes, the identification and characterization of these complexes is currently an area of intense scientific interest both from a basic and applied perspective. As a result, there is a high demand for novel tools that can isolate proteins associated with a specific target RNA.
Over the past few years, we have developed the ARiBo technology, which provides a quick and efficient procedure for purifying RNA. Although this procedure was originally developed to rapidly purify in vitro transcribed RNA, it also shows great potential for isolating ribonucleoprotein complexes associated with a specific target RNA. Here, we propose to exploit the ARiBo technology to further develop reagents and procedures that can be packaged as kits for isolating ribonucleoprotein complexes. Our technology may become the ultimate solution for isolating RNA-protein complexes in riboproteomics approaches with potential market opportunities in many fields, including in identifying and validating new drug targets. Thus the research proposed here has great potential to open new possibilities for life sciences research and have a positive impact on the health of Canadians as well as upon the Canadian economy.
Competitiondate
201202
Approvedterm2
1 yr 0 mth
Pinamesdelim
Legault, Pascale
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $145,412~ $13,349~